NCT02159989View on ClinicalTrials.gov

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 18, 2014

Primary Completion Date

June 29, 2021

Study Completion Date

January 29, 2024

Conditions

Advanced Malignant Solid NeoplasmFibrolamellar CarcinomaMetastatic Malignant Solid NeoplasmOvarian CarcinomaPancreatic Neuroendocrine TumorRecurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Solid Neoplasm

Interventions

DRUG

Sapanisertib

Given PO

BIOLOGICAL

Ziv-Aflibercept

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02159989 - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter